RedHill Biopharma enrols last patient in Phase II irritable bowel syndrome trial
European Pharmaceutical Review | April 26, 2017
RedHill Biopharma has enrolled the last patient in the Phase II study with Bekinda (RHB-102) 12 mg for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).